+

WO2001007041A1 - Medicament anti-arythmique - Google Patents

Medicament anti-arythmique Download PDF

Info

Publication number
WO2001007041A1
WO2001007041A1 PCT/BG2000/000020 BG0000020W WO0107041A1 WO 2001007041 A1 WO2001007041 A1 WO 2001007041A1 BG 0000020 W BG0000020 W BG 0000020W WO 0107041 A1 WO0107041 A1 WO 0107041A1
Authority
WO
WIPO (PCT)
Prior art keywords
drug
hydrochloride
amiodarone
well
amiοdaροn
Prior art date
Application number
PCT/BG2000/000020
Other languages
English (en)
Russian (ru)
Inventor
Plamen Kubratov Tsvetkov
Evtimiya Ivanova Stefanova
Stefan Krumov Kafedzhiiski
Simeon Ivanov Stoyanov
Nadezhda Georgieva Tsaneva
Original Assignee
Balkanpharma Holding Ad
Balkanpharma Dupnitza Ad
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EA200100275A priority Critical patent/EA003052B1/ru
Application filed by Balkanpharma Holding Ad, Balkanpharma Dupnitza Ad filed Critical Balkanpharma Holding Ad
Priority to AU62558/00A priority patent/AU6255800A/en
Publication of WO2001007041A1 publication Critical patent/WO2001007041A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Definitions

  • ammonium hydroxide they are mixed with 40 weight percent micro-crystalline cellulose (Witzel ⁇ 102) and 64 weight percent water.
  • the Rhythmic Medicinal Product is used using the following process mode:
  • a large quantity of amidodrum hydrated and sweetened with sodium gluten is at a loss of 2.3: 1 and is switched off. and the composition is moisturized with a compound of ⁇ 64 and 96% ethanol.
  • Moisturized mass is allowed to be granulated and dried at a temperature of 40 - 50 ° ⁇ to obtain residual moisture in the amount of 3% and is not allowed to be consumed.
  • a dry granule a ⁇ 200 manifold is added, a basic oxide brown, talc and magnesium stearate. After homogenization from the mixture, the tablets are manufactured on a portable laptop with flat plugs with a diameter of 10 mm with an integrated and separate line.
  • the invention may be clarified on the basis of the following examples: REMARK 1.
  • ⁇ ezul ⁇ a ⁇ y is ⁇ y ⁇ any ⁇ ⁇ g ⁇ on s ⁇ e ⁇ en ⁇ as ⁇ v ⁇ eniya ami ⁇ da ⁇ n gid ⁇ l ⁇ ida of s ⁇ s ⁇ ava ⁇ lezn ⁇ y m ⁇ deli ⁇ edl ⁇ zhenn ⁇ g ⁇ le ⁇ a ⁇ s ⁇ venn ⁇ g ⁇ s ⁇ eds ⁇ va ⁇ i ⁇ able ⁇ a ⁇ ami ⁇ da ⁇ na ⁇ 200 mg s ⁇ avni ⁇ elny ⁇ ⁇ b ⁇ azts ⁇ v, ⁇ a ⁇ zhe s ⁇ de ⁇ zhaschi ⁇ 200 mg ami ⁇ da ⁇ n gid ⁇ l ⁇ ida ⁇ eds ⁇ avleny in ⁇ ablitse
  • the area at the front ( ⁇ ) at the plasma concentration is available (from 0 to 24 ⁇ ) at the place of the owner, (it is completely)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne un médicament anti-arythmique qui contient (2-bytil-3-benzofuranil)[4-[2-(dyéthylamino)éthoxy]-3,5-diiodophényl]méthanone hydrochloride, connu sous le nom générique de 'amiodarone' et utilisé dans la pratique médicale en tant que produit anti-arythmique pour le traitement de la tachycardie, des extrasystoles et des perturbations du rythme cardiaque ainsi que dans la prévention des rechutes. L'objet de l'invention concerne un médicament se présentant sous la forme de comprimés comprenant 200 mg d'amiodarone hydrochloride, avec un rapport de 2,3: 1 entre l'amiodarone hydrochloride et l'amidon de maïs avec de l'amidon glycolate de sodium, le médicament étant constitué de ce qui suit: entre 100 et 300 mg d'amiodarone hydrochloride, entre 40 et 90 mg d'amidon de maïs, entre 10 et 30 mg d'amidon glycolate de sodium, entre 15 et 35 mg de mannitol SD 200, entre 0,5 et 35 mg de dioxyde de silicium colloïdal, entre 6 et 18 mg de copolyvidone VA 64, entre 6 et 15 mg de talc et entre 1 et 5 mg de stéarate de magnésium. Selon l'invention, ce médicament est caractérisé par sa composition simplifiée; en outre, les adjuvants sélectionnés lui confèrent des caractéristiques physico-chimiques exceptionnelles, un degré plus élevé de solubilité in vitro du composant actif ainsi que des taux thérapeutiques dans le plasma confirmés par des recherches de bioéquivalence.
PCT/BG2000/000020 1999-07-27 2000-07-27 Medicament anti-arythmique WO2001007041A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EA200100275A EA003052B1 (ru) 1999-07-27 2000-07-21 Антиаритмическое лекарственное средство
AU62558/00A AU6255800A (en) 1999-07-27 2000-07-27 Antiarrhythmic drug

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
BG103607 1999-07-27
BG10360799 1999-07-27

Publications (1)

Publication Number Publication Date
WO2001007041A1 true WO2001007041A1 (fr) 2001-02-01

Family

ID=3927839

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/BG2000/000020 WO2001007041A1 (fr) 1999-07-27 2000-07-27 Medicament anti-arythmique

Country Status (4)

Country Link
AU (1) AU6255800A (fr)
EA (1) EA003052B1 (fr)
LT (1) LT4899B (fr)
WO (1) WO2001007041A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2223759C1 (ru) * 2002-09-18 2004-02-20 Виктор Павлович Кутняк Антиаритмический препарат
US10894049B2 (en) 2016-03-29 2021-01-19 Shenzhen Pharmacin Co., Ltd. Pharmaceutical formulation of palbociclib and a preparation method thereof
US11471418B2 (en) 2020-09-29 2022-10-18 Shenzhen Pharmacin Co., Ltd. Pharmaceutical compositions of amorphous solid dispersions and methods of preparation thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997034597A1 (fr) * 1996-03-18 1997-09-25 Sanofi Utilisation de composes antiarythmiques dans la reduction de la mortalite post infarctus
WO1998046214A1 (fr) * 1997-04-11 1998-10-22 Upsher-Smith Laboratories, Inc. Comprime pharmaceutique de sel d'amiodarone

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE108996T1 (de) 1988-02-25 1994-08-15 Brocades Pharma Bv Verfahren zur herstellung eines pharmazeutischen granulats.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997034597A1 (fr) * 1996-03-18 1997-09-25 Sanofi Utilisation de composes antiarythmiques dans la reduction de la mortalite post infarctus
WO1998046214A1 (fr) * 1997-04-11 1998-10-22 Upsher-Smith Laboratories, Inc. Comprime pharmaceutique de sel d'amiodarone

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MASHKOVSKY M.D., "Lekarstvennye sredstva", Moscow, Meditsina, 1986, pages 425- 426. *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2223759C1 (ru) * 2002-09-18 2004-02-20 Виктор Павлович Кутняк Антиаритмический препарат
US10894049B2 (en) 2016-03-29 2021-01-19 Shenzhen Pharmacin Co., Ltd. Pharmaceutical formulation of palbociclib and a preparation method thereof
US11471418B2 (en) 2020-09-29 2022-10-18 Shenzhen Pharmacin Co., Ltd. Pharmaceutical compositions of amorphous solid dispersions and methods of preparation thereof

Also Published As

Publication number Publication date
LT4899B (lt) 2002-03-25
EA003052B1 (ru) 2002-12-26
AU6255800A (en) 2001-02-13
LT2001034A (en) 2001-10-25
EA200100275A1 (ru) 2001-08-27

Similar Documents

Publication Publication Date Title
EP0965339B1 (fr) Preparation de nateglinide en comprimes
US4708868A (en) Oral anti-diabetic pharmaceutical forms and the preparation thereof
US4556678A (en) Sustained release propranolol tablet
CA1228299A (fr) Preparation galenique d'agents antidiabetiques administres par voie orale et procede de production
US5547993A (en) Therapeutic agent for glaucoma
EP0249347A2 (fr) Composition à libération contrôlée de dihydrocodéine
EP0231826A2 (fr) Comprimé de théophylline à libération retardée
JP2002529407A (ja) Ｌ−ｄｏｐａエチルエステル含有分散性組成物
AU2001270484B2 (en) Use of bradycardiac substances in the treatment of myocardial diseases associated with hypertrophy and novel medicament combinations
HU228179B1 (en) Pharmaceutical, oral compositions containing 5-ht4 agonists or antagonists as active agent
KR101136655B1 (ko) 레보타이록신 나트륨을 포함하는 제약 제제
CZ147494A3 (en) Pharmaceutical preparation and process for preparing thereof
KR100366130B1 (ko) 항과혈당증작용을지닌약제
KR20070119714A (ko) 리오티로닌의 제어 방출 의약 조성물 및 그의 제조 및 사용방법
WO2001007041A1 (fr) Medicament anti-arythmique
WO2012050483A1 (fr) Procédé de production et d'utilisation d'un copolymère de carboxyméthylcellulose de sodium et de gossypol
EP0064388B1 (fr) Compositions pharmaceutiques orales à effet retardé
CN114191404B (zh) 一种多替拉韦片剂及其制备方法
IE66378B1 (en) Solid oral forms of application containing ifosfamide as active substance
EP0005733B1 (fr) Compositions pharmaceutiques pour application dans le traitement de la néphropathie diabétique et procédé pour leur préparation
JP3116970B2 (ja) ペミロラストカリウムの徐放性製剤
JPH09255569A (ja) ロキソプロフェン・ナトリウム含有錠剤製剤
CN114917213B (zh) 包含阿米替林的精神疾病治疗剂和治疗精神疾病的方法
US3642993A (en) Pharmaceutical composition containing 2-methyl - 5 - phenyl - 1 2-dihydro-3h-2-benzazepine for treatment of a condition associated with anxiety or tension
KR100788454B1 (ko) 속효성이 증진된 나테글리니드를 유효성분으로 함유하는약제학적 조성물

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AM AT AT AU AZ BA BY CN CZ CZ DE DE DK DZ EE EE ES FI FI GE GH HR HU IL IN KG KP KZ LT LV MD MK PL RO RU SD SI SK SK TJ TM TR UA UZ VN YU ZA ZW

WWE Wipo information: entry into national phase

Ref document number: 200100275

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: A 2001 00347

Country of ref document: RO

WWE Wipo information: entry into national phase

Ref document number: 2001034

Country of ref document: LT

WWP Wipo information: published in national office

Ref document number: 2001034

Country of ref document: LT

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 2001034

Country of ref document: LT

WWW Wipo information: withdrawn in national office

Ref document number: 2001034

Country of ref document: LT

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载